KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $530.2 million.

  • Novavax's Cash & Equivalents fell 53.28% to $268.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.0 million, marking a year-over-year decrease of 53.28%. This contributed to the annual value of $530.2 million for FY2024, which is 6.73% down from last year.
  • As of FY2024, Novavax's Cash & Equivalents stood at $530.2 million, which was down 6.73% from $568.5 million recorded in FY2023.
  • In the past 5 years, Novavax's Cash & Equivalents registered a high of $1.5 billion during FY2021, and its lowest value of $530.2 million during FY2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $568.5 million (2023), whereas its average is $811.9 million.
  • In the last 5 years, Novavax's Cash & Equivalents soared by 602.08% in 2020 and then tumbled by 57.48% in 2023.
  • Over the past 5 years, Novavax's Cash & Equivalents (Yearly) stood at $553.4 million in 2020, then spiked by 173.78% to $1.5 billion in 2021, then dropped by 11.76% to $1.3 billion in 2022, then tumbled by 57.48% to $568.5 million in 2023, then fell by 6.73% to $530.2 million in 2024.